PMID: 3770870Nov 1, 1986Paper

Hypertensive effect of a bradykinin antagonist in normotensive rats

Hypertension
A BenetosH Gavras

Abstract

The purpose of these experiments was to study the possible contribution of bradykinin to normal blood pressure maintenance. The bradykinin analogue B4146, a competitive antagonist-partial agonist of bradykinin, was used in three groups of normotensive unanesthetized Wistar rats. Two intra-aortic injections of B4146 (1 mg in 0.2 ml of dextrose) were given 5 minutes apart (i.e., well after return of blood pressure to baseline, which occurred within 68 +/- 19 seconds). One group had been pretreated with the angiotensin converting enzyme inhibitor HOE 498, 1 mg/kg (Hoechst), and one received only dextrose as the first injection to serve as controls. The bradykinin antagonist produced an average increase in mean arterial pressure of approximately 13 mm Hg for all groups. In five animals, however, the first injection of B4146 produced a hypotensive effect, whereas the second one consistently produced a rise in blood pressure. Pretreatment with the angiotensin converting enzyme inhibitor did not affect the magnitude of the subsequent blood pressure increase in response to B4146. Since smaller doses of B4146, sufficient to block exogenous bradykinin, do not cause changes in normal blood pressure, we conclude that endogenous bradykinin ...Continue Reading

References

Apr 1, 1979·The Journal of Clinical Endocrinology and Metabolism·J H MerseyT J Moore
Jan 11, 1976·Proceedings of the Society for Experimental Biology and Medicine·H R KeiserJ J Pisano
Jan 1, 1984·Clinical and Experimental Hypertension. Part A, Theory and Practice·M YasujimaK Omata
Dec 1, 1982·Canadian Journal of Physiology and Pharmacology·D RegoliS Caranikas
Feb 1, 1980·The Journal of Clinical Investigation·O B HollandH Braunstein

❮ Previous
Next ❯

Citations

Apr 1, 1990·Medicinal Research Reviews·R M BurchL R Steranka
Oct 19, 1987·Life Sciences·R B MoffettA Husain
Jan 1, 1989·Life Sciences·M A TaylorA R Gear
Aug 23, 2002·Pharmacology & Therapeutics·Bilkish CassimKanti Bhoola
Jan 1, 1995·Canadian Journal of Physiology and Pharmacology·I LebrunA C Camargo
Oct 1, 1995·Canadian Journal of Physiology and Pharmacology·J DuanD Mathis
Jan 1, 1990·Clinical and Experimental Hypertension. Part A, Theory and Practice·T TakenakaT Saruta
Jan 1, 1991·Clinical and Experimental Hypertension. Part A, Theory and Practice·M G MarlettiniC Orlandi
Apr 1, 1988·The American Journal of the Medical Sciences·I Gavras, H Gavras
Oct 1, 1992·Kidney International·I Gavras
Apr 10, 2009·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·S A BarretoI Lebrun
Sep 1, 1991·Hypertension·O A Carretero, A G Scicli
May 1, 1988·Hypertension·M Nakagawa, A Nasjletti
Feb 1, 1988·Hypertension·L F CarbonellA G Scicli
Oct 1, 1990·Hypertension·L DanckwardtT Unger
Feb 1, 1993·Hypertension·D J CampbellA M Duncan
Oct 15, 2003·Hypertension·Irena DukaHaralambos Gavras
Mar 2, 2006·American Journal of Physiology. Endocrinology and Metabolism·Arvi DukaHaralambos Gavras
Jun 1, 1991·International Journal of Peptide and Protein Research·M S DeshpandeJ Burton
Sep 15, 2001·American Journal of Physiology. Heart and Circulatory Physiology·E KintsurashviliH Gavras

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.